As of Wednesday, February 18, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 8.15%, which has investors questioning if this is right time to buy.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in ...
This substantial runway provides a buffer as the company navigates the costly clinical trial process. Cartesian operates within a dynamic and evolving segment of the biopharmaceutical industry. A ...
A look at the shareholders of Cartesian Growth Corporation (NASDAQ:GLBL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Cartesian has been ...
The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results